Background {#Sec1}
==========

Initial antibiotic therapy affects outcomes in severe infection. For empiric therapy to have a benefit on patient outcomes, it must not only be given in a timely manner but must also be active in vitro against the infecting pathogen. Many studies indicate that either delaying antibiotic therapy or selecting a treatment to which the infecting pathogen is non-susceptible increases the risk for death 2--5-fold \[[@CR1]--[@CR13]\]. Therefore, clinicians must be aware of the common pathogens in specific infectious syndromes and of local antimicrobial susceptibility patterns in order to make appropriate choices for antimicrobial therapies. Unfortunately, rapidly rising rates of resistance and shifting resistance patterns render ensuring appropriate empiric coverage a challenge \[[@CR14]\].

Recently, the Centers for Disease Control and Prevention have identified carbapenem-resistance among Enterobacteriaceae as an urgent threat in the US \[[@CR15]\]. Though Enterobacteriaceae are common pathogens in pneumonia, urinary tract infections and sepsis and thus are often treated in most empiric coverage recommendations, the escalating frequency of carbapenem resistance in these pathogens makes ensuring initially appropriate antimicrobial treatment in areas where carbapenem-resistant Enterobacteriaceae (CRE) are prevalent nearly impossible \[[@CR13], [@CR14], [@CR16]--[@CR19]\]. Furthermore, administering broad-spectrum agents to all severely ill patients in order not to miss some individual with a rare highly resistant pathogen is not a sustainable practice, since the concerns for promoting further resistance may outweigh any potential benefit to patient-specific outcomes. In this way, the dilemma of CREs amplifies the tension between public (preservation of antimicrobial activity) and patient-level (optimizing clinical outcomes) health imperatives.

It remains unclear if the nexus between inappropriate therapy and outcomes seen with other pathogens exists in the case of infections due to CRE. Few analyses have specifically addressed this issue, while some that have attempted this lacked the ability to delineate the impact of inappropriate empiric therapy of CREs on attributable morbidity or on resources such as length of stay (LOS) \[[@CR20], [@CR21]\]. To understand better the relationship between carbapenem-resistance, choice of inappropriate empiric therapy (IET), and key hospital outcomes, we conducted a cohort study of patients admitted to the hospital with community-onset urinary tract infections (UTI), pneumonia and sepsis due to Enterobacteriaceae.

Methods {#Sec2}
=======

This was a multi-center retrospective cohort study of patients admitted to the hospital with pneumonia, sepsis and UTI (referred to from here on as "UTI"), or sepsis from another source in the Premier Research database in the years 2009--2013. We hypothesized that infection with a CRE phenotype increased the risk of receiving IET. In turn, we hypothesized that the receipt of IET is adversely associated with hospital mortality, LOS, and costs.

Because this study used already existing fully de-identified retrospective data, it was exempt from IRB review.

Since the data source was the same and methods utilized in this study were similar to those used in our previous study, please refer to that paper for details \[[@CR22]\].

Patient population {#Sec3}
------------------

Patients were included if they were adults (age ≥ 18 years) hospitalized with a UTI International Classification of Diseases, version 9, Clinical Modification (ICD-9-CM) codes (principal diagnosis 112.2, 590.1, 590.11, 590.2, 590.3, 590.8.590.81, 595, 597, 599 or 996.64, or principal sepsis diagnosis \[see below\] with UTI as a secondary diagnosis), pneumonia ICD-9-CM codes (principal diagnosis 481--486, or respiratory failure codes \[518.81 or 518.84\] with pneumonia as a secondary diagnosis) or sepsis codes from another source (principal diagnosis 038, 038.9, 020.0, 790.7, 995.92 or 785.52, or respiratory failure codes \[518.81 or 518.84\] with sepsis coded as a secondary diagnosis) \[[@CR23]--[@CR27]\]. In order to eliminate confounding of the outcomes by pre-infection onset hospital events, only patients with infection present on admission, as evidenced by antibiotic treatment beginning within the first 2 days of hospitalization and continuing for at least 3 consecutive days, or until discharge, were included \[[@CR24]--[@CR26]\]. Patients were excluded if they were transferred from another acute care facility, if they were diagnosed with cystic fibrosis, or if their hospital length of stay (LOS) was 1 day or less. Those who met criteria for both UTI and sepsis or pneumonia and sepsis were included in the UTI or pneumonia group, respectively. Those with both UTI and pneumonia were analyzed with the pneumonia group. Patients were followed until death in or discharge from the hospital.

Data source {#Sec4}
-----------

The data for the study derived from Premier Research database, an electronic laboratory, pharmacy and billing data repository, for years 2009 through 2013, which contains approximately 15% of all hospitalizations nationwide. For detailed description of the dataset, please, refer to citation \#22.

Baseline variables {#Sec5}
------------------

We classified each community-onset infection (UTI, pneumonia or sepsis) as healthcare-associated (HCA) if one or more of the following risk factors was present: 1) prior hospitalization within 90 days of the index hospitalization, 2) hemodialysis, 3) admission from a long-term care facility, 4) immune suppression \[[@CR3], [@CR6], [@CR16], [@CR23]--[@CR26]\]. All other infections were considered to be community-acquired (CA). For other patient factors and hospital-level variables, please see citation \#22.

Microbiology and treatment variables and definitions {#Sec6}
----------------------------------------------------

Urinary, blood and respiratory cultures had to be obtained within the first 2 days of hospitalization.

The following organisms were defined as Enterobacteriaceae of interest:*Escherichia coliKlebsiella pneumoniaeKlebsiella oxytocaEnterobacter cloacaeEnterobacter aerogenesProteus mirabilisProteus spp.Serratia marcescensCitrobacter freundiiMorganella morganiiProvidencia spp.*

Premier database receives organism susceptibility reports from individual institutions' laboratories as S (susceptible), I (intermediate) or R (resistant). Although no MIC data are available in the database, all microbiology testing was performed locally at the institutions contributing the data and conformed to the CLSI standards. Carbapenem-resistant Enterobacteriaceae were defined as one of the above organisms where susceptibility testing yielded an I or R result to at least one of the four carbapenems: imipenem, meropenem, ertapenem or doripenem.

IET was present if the antibiotic administered for the infection did not cover the organism or if appropriate coverage did not start within 2 days of the positive culture being obtained.

Statistical analyses {#Sec7}
--------------------

We compared characteristics of patients infected with CRE to those infected with carbapenem-susceptible Enterobacteriaceae (CSE) and those treated with IET to those treated with non-IET. All unadjusted comparisons were done using standard methods described in detail in citation \#22.

We developed a generalized logistic regression model to explore the relationship between CRE and the risk of IET. Covariates in the model were identical to those in citation \#22. We calculated the relative risk ratio with 95% confidence intervals of receiving IET for CRE vs. CSE based on Huber-White robust standard errors clustered at the hospital level \[[@CR28]\]. Consistent with our prior study, we confirmed our results in a non-parse model and a propensity matched model with propensity for CRE derived from a logistic regression model using the non-parse model's predictors \[[@CR22]\]. To explore the impact of IET on hospital mortality, LOS and costs, we developed hierarchical regression models with hospitals as random effects along with confirmatory propensity-matched models.

All tests were two-tailed, and a *p* value \<0.05 was deemed a priori to represent statistical significance. All analyses were performed in Stata/MP 13.1 for Windows (StataCorp LP, College Station, TX).

Results {#Sec8}
=======

Among 230,086 patients presenting to the hospital with a UTI, pneumonia or sepsis, 40,137 (17.4%) met the inclusion criteria for Enterobacteriaceae of which the majority were UTI (54.2%), with the remainder either pneumonia (13.1%) or sepsis (32.7%). Among all patients with Enterobacteriaceae, 1227 (3.1%) had 1938 CRE organisms (Table [1](#Tab1){ref-type="table"}). The prevalence of CRE among the Enterobacteriaceae ranged from 2.9% in UTI to 3.6% in pneumonia. Notably, over 85% of patients in both the CRE and CSE groups had a sepsis diagnosis code at some point during the hospitalization.Table 1Individual CRE organisms and their frequenciesCRE organism nameCRE organism Count% of Total CRE% of the Total patients^a^(*N* = 1938)(*N* = 1938)(*N* = 1227)*Klebsiella pneumoniae*72437.4%59.0%*Proteus mirabilis*37019.1%30.2%*Escherishia coli*29415.2%24.0%*Enterobacter cloacae*1286.6%10.4%*Providencia spp*944.9%7.7%*Serratia marcescens*874.5%7.1%*Morganella morganii*874.5%7.1%*Enterobacter aerogenes*402.1%3.3%*Proteus spp.*271.4%2.2%*Citrobacter freundii*271.4%2.2%*Klebsiella oxytoca*221.1%1.8%*Enterobacter other*130.7%1.1%*Citrobacter other*140.7%1.1%*Serratia other*60.3%0.5%*Klebsiella other*50.3%0.4%^a^Sum adds up to \>100%, as some patients had \>1 CRE organism

Those with CRE were younger (66.6+/−15.3 vs. 69.1+/−15.9 years, *p* \< 0.001), and more likely to be African-American (19.7% vs. 14.0%, *p* \< 0.001) than those with CSE. Many of the individual chronic conditions were more prevalent in the CRE than CSE group, and the mean Charlson comorbidity index reflected this (2.0+/−2.0 vs. 1.9+/−2.1, *p* = 0.009) (Table [2](#Tab2){ref-type="table"}). CRE was more common than CSE in the West and the Northeast, in urban hospitals, in those of medium size (200--499 beds) and in teaching hospitals (*p* \< 0.001 for each comparison) (Table [2](#Tab2){ref-type="table"}). Large hospitals (500+ beds) were less likely to have CRE than CSE (Table [2](#Tab2){ref-type="table"}).Table 2Baseline characteristicsCSE%CRE%*P*-value*N* = 38,910*N* = 1227Mean age, years (SD)69.1 (15.9)66.6 (15.3)\<0.001Gender: male16,27341.8%64252.3%\<0.001Race White28,29572.7%82166.9%\<0.001 Black546414.0%24219.7% Hispanic10692.7%322.6% Other408210.5%13210.8%Admission Source Non-healthcare facility (including from home)25,55965.7%77663.2%\<0.001 Clinic12853.3%272.2% Transfer from ECF36979.5%26621.7% Transfer from another non-acute care facility4731.2%221.8% Emergency Department776620.0%13210.8% Other1300.3%40.3%Elixhauser Comorbidities Congestive heart failure962324.7%32926.8%0.096 Valvular disease31128.0%967.8%0.825 Pulmonary circulation disease23236.0%937.6%0.020 Peripheral vascular disease428511.0%16913.8%0.002 Paralysis408510.5%27122.1%\<0.001 Other neurological disorders866822.3%34828.4%\<0.001 Chronic pulmonary disease11,03528.4%37130.2%0.151 Diabetes without chronic complications11,61629.9%42034.2%0.001 Diabetes with chronic complications38099.8%14111.5%0.049 Hypothyroidism676417.4%22418.3%0.428 Renal failure10,81027.8%44636.3%\<0.001 Liver disease20845.4%655.3%0.929 Peptic ulcer disease with bleeding170.0%10.1%0.428 AIDS120.0%00.0%1.000 Lymphoma6041.6%211.7%0.657 Metastatic cancer17874.6%403.3%0.027 Solid tumor without metastasis15694.0%342.8%0.026 Rheumatoid arthritis/collagen vascular17214.4%453.7%0.204 Coagulopathy535013.7%13911.3%0.015 Obesity609515.7%19115.6%0.926 Weight loss685517.6%34027.7%\<0.001 Fluid and electrolyte disorders21,33254.8%37830.8%0.764 Chronic blood loss anemia5451.4%242.0%0.105 Deficiency anemia15,15438.9%59848.7%\<0.001 Alcohol abuse13673.5%332.7%0.122 Drug abuse9232.4%352.9%0.278 Psychosis23586.1%816.6%0.435 Depression585415.0%17414.2%0.404 Hypertension24,93864.1%78163.7%0.752Charlson Comoribidity Score 012,01030.9%33427.2%\<0.001 1785520.2%23018.7% 2790220.3%24419.9% 3511813.2%18014.7% 428977.4%14611.9% 5+31288.0%937.6% Mean (SD)1.9 (2.1)2.0 (2.0)0.009 Median \[IQR\]1 \[0,3\]2 \[0, 3\]\<0.001Hospital Characteristics Census region  Midwest10,53127.1%28823.5%\<0.001  Northeast529713.6%33627.4%  South16,20341.6%31025.3%  West687917.7%29323.9%Number of Beds  \< 200658916.9%19215.6%\<0.001 200 to 299877922.6%33827.5% 300 to 49912,69132.6%42134.3% 500+10,85127.9%27622.5% Teaching14,60937.5%56646.1%\<0.001 Urban35,07990.2%116795.1%\<0.001*CSE* carbapenem sensitive Enterobacteriaceae, *CRE* carbapenem resistant Enterobacteriaceae, *SD* standard deviation, *ECF* extended care facility, *AIDS* acquired immune deficiency syndrome, *IQR* interquartile range

In both the CRE and CSE groups, over one-half the patients had the diagnosis of UTI, with the remaining divided between sepsis (33.3% CRE vs. 32.7% CSE) and pneumonia (15.2% CRE vs. 13.0% CSE) (Table [2](#Tab2){ref-type="table"}). Patients infected with CRE were more likely to have a HCA infection (58.5% vs. 35.4%, *p* \< 0.001) along with a greater illness severity by day 2 of admission (ICU 56.0% vs. 40.8%, *p* \< 0.001; mechanical ventilation 35.6% vs. 15.7%, *p* \< 0.001; though not vasopressors 16.7% vs. 14.9%, *p* = 0.081) than CSE patients (Table [3](#Tab3){ref-type="table"}). Although among the CRE group there was a higher prevalence of empiric use of carbapenems, aminoglycosides and polymyxins than in those eventually found to be infected with a CSE, those with CRE infections were also significantly more likely to receive IET (52.8% vs. 11.1%, *p* \< 0.001). Unadjusted hospital mortality median LOS and costs among CRE were also significantly greater than CSE, and these differences held across all infection types (Table [3](#Tab3){ref-type="table"}).Table 3Infection characteristics, treatment and outcomesCSE%CRE%*P*-value*N* = 38,910*N* = 1227Infection characteristics Sepsis12,72632.7%40933.3%0.039 Pneumonia506013.0%18715.2% UTI21,12454.3%63151.4% HCA13,78235.4%71858.5%\<0.001Illness severity measures by day 2 ICU admission15,87640.8%68756.0%\<0.001 Mechanical ventilation609215.7%43735.6%\<0.001 Vasopressors579814.9%20516.7%0.081Antibiotics administered by day 2 Aminoglycosides38439.9%24219.7%\<0.001 Antipseudomonal penicillins640316.5%31325.5%\<0.001 Antipseudomonal floroquinolones18,46847.5%40633.1%\<0.001 Antipseudomonal penicillins with beta-lactamase inhibitors19,72750.7%61750.3%0.775 Extended spectrum cephalosporins13,32734.3%41533.8%0.755 Folate pathway inhibitors2510.6%121.0%0.155 Penicillins with beta-lactamase inhibitors8542.2%262.1%0.837 Polymyxins1260.3%242.0%\<0.001 Tetracyclines2480.6%60.5%0.519 Tigecycline5861.5%867.0%\<0.001 Aztreonam17404.5%564.6%0.878Empiric treatment appropriateness Non-IET32,19782.7%51341.8%\<0.001 IET433611.1%64852.8% Indeterminate23376.0%665.4%*Hospital outcomes* Mortality395810.2%17814.5%\<0.001 Mean (SD) LOS, days9.6 (10.7)15.6 (17.4)\<0.001 Median \[IQR\] LOS, days7 \[4, 11\]10 \[6, 18\]\<0.001 Mean (SD) costs, \$20,601 (29702)38,494 (46,964)\<0.001 Median \[IQR\] costs, \$13,020 \[7501, 24,237\]22,909 \[12,988, 42,815\]\<0.001*Hospital outcomes stratified by infection type* UTI  Mortality18738.9%7812.4%0.002  Mean (SD) LOS, days9.0 (9.4)14.6 (15.9)\<0.001  Median \[IQR\] LOS, days7 \[4, 11\]10 \[6, 17\]\<0.001  Mean (SD) costs, \$19,036 (24,494)33,400 (37,662)\<0.001  Median \[IQR\] costs, \$12,082 \[7104, 21,822\]21,154 \[12,687, 39,374\]\<0.001 Sepsis  Mortality166013.0%8119.8%\<0.001  Mean (SD) LOS, days10.9 (12.6)18.0 (20.8)\<0.001  Median \[IQR\] LOS, days7 \[4, 13\]11 \[7, 21\]\<0.001  Mean (SD) costs, \$26,793 (37,390)50,038 (60,602)\<0.001  Median \[IQR\] costs, \$15,614 \[8584, 30,317\]27,264 \[14,581, 57,825\]\<0.001 Pneumonia  Mortality4258.4%1910.2%0.395  Mean (SD) LOS, days9.2 (10.4)13.4 (13.0)\<0.001  Median \[IQR\] LOS, days7 \[4, 10\]9 \[6, 16\]\<0.001  Mean (SD) costs, \$19,250 (25,743)30,432 (35,089)\<0.001  Median \[IQR\] costs, \$11,826 \[7076, 21,100\]19,820 \[12,220, 35,713\]\<0.001*CSE* carbapenem sensitive Enterobacteriaceae, *CRE* carbapenem resistant Enterobacteriaceae, *UTI* urinary tract infection, *HCA* healthcare-associated, *ICU* intensive care unit, *IET* inappropriate empiric therapy

Comparing the cohort of 37,694 patients (93.9% of all patients with Enterobacteriaceae) with valid antimicrobial treatment data, 32,710 (86.8%) received appropriate therapy (Table [4](#Tab4){ref-type="table"}). While patients receiving appropriate empiric therapy were more likely to have UTI or sepsis than those in the IET group, the frequency of pneumonia was higher among patients on IET (20.0%) than those on appropriate treatment (12.0%) (*p* \< 0.001) (Table [4](#Tab4){ref-type="table"}). As for the unadjusted hospital outcomes, mortality was higher in patients receiving IET than appropriate therapy (12.2% vs. 9.9%, *p* \< 0.001). Both LOS and costs were significantly higher in the IET group than in the group receiving non-IET (Table [4](#Tab4){ref-type="table"}). These relationships generally held irrespective of the infection type (Table [4](#Tab4){ref-type="table"}).Table 4Characteristics of the cohort based on the receipt of inappropriate empiric treatmentNon-IET%IET%*P*-value*N* = 32,710*N* = 4984*Baseline characteristics* Mean age, years (SD)69.0 (16.0)69.4 (15.3)0.094 Gender: male13,68041.8%216943.5%0.024 Race  White23,92173.1%344369.1%\<0.001  Black438413.4%86217.3%  Hispanic9192.8%1633.3%  Other348610.7%51610.4% Admission Source  Non-healthcare facility (including from home)21,45065.6%303460.9%\<0.001  Clinic10933.3%1382.8%  Transfer from ECF29969.2%75915.2%  Transfer from another non-acute care facility3791.2%771.5%  Emergency Department668820.4%95919.2%  Other1040.3%170.3% Elixhauser Comorbidities  Congestive heart failure783624.0%150930.3%\<0.001  Valvular disease25947.9%4258.5%0.148  Pulmonary circulation disease19125.8%3587.2%\<0.001  Peripheral vascular disease356410.9%57711.6%0.152  Paralysis328910.1%77015.4%\<0.001  Other neurological disorders722722.1%126925.5%\<0.001  Chronic pulmonary disease907927.8%166333.4%\<0.001  Diabetes without chronic complications969529.6%162332.6%\<0.001  Diabetes with chronic complications31529.6%52410.5%0.052  Hypothyroidism564517.3%94218.9%0.004  Renal failure902427.6%154030.9%\<0.001  Liver disease17745.4%2454.9%0.138  Peptic ulcer disease with bleeding150.0%20.0%1.000  AIDS80.0%40.1%0.063  Lymphoma5081.6%741.5%0.716  Metastatic cancer15434.7%1823.7%0.001  Solid tumor without metastasis13354.1%1633.3%0.006  Rheumatoid arthritis/collagen vascular14224.3%2154.3%0.914  Coagulopathy462614.1%54010.8%\<0.001  Obesity507915.5%82216.5%0.081  Weight loss558317.1%111722.4%\<0.001  Fluid and electrolyte disorders17,96154.9%270254.2%0.357  Chronic blood loss anemia4591.4%791.6%0.313  Deficiency Anemia12,73538.9%209642.1%\<0.001  Alcohol abuse11393.5%1633.3%0.446  Drug abuse7892.4%1032.1%0.135  Psychosis19796.1%2945.9%0.676  Depression485914.9%80616.2%0.018  Hypertension20,98764.2%315463.3%0.229 Charlson Comoribidity Score  010,35331.7%123924.9%\<0.001  1651719.9%107221.5%  2659520.2%104721.0%  3422312.9%75715.2%  424007.3%4659.3%  5+26228.0%4048.1%  Mean (SD)1.9 (2.1)2.0 (2.0)\<0.001  Median \[IQR\]1 \[0, 3\]2 \[1 3\]\<0.001*Infection characteristics and treatment* Infection characteristics  Sepsis10,73632.8%146829.5%\<0.001  Pneumonia393612.0%99520.0%  UTI18,03855.1%252150.6%  HCA11,41334.9%222144.6%\<0.001  CRE5131.6%64813.0%\<0.001 Illness severity  ICU admission13,52441.3%207441.6%0.720  Mechanical ventilation506415.5%106221.3%\<0.001  Vasopressors492915.1%70914.2%0.111 Antibiotics administered  Aminoglycosides369411.3%3517.0%\<0.001  Antipseudomonal penicillins619919.0%3477.0%\<0.001  Antipseudomonal floroquinolones15,99548.9%248049.8%0.258  Antipseudomonal penicillins with beta-lactamase inhibitors16,87451.6%200840.3%\<0.001  Extended spectrum cephalosporins12,17437.2%113422.8%\<0.001  Folate pathway inhibitors2250.7%360.7%0.809  Penicillins with beta-lacatamase inhibitors6812.1%1472.9%0.005  Polymyxins1020.3%320.6%\<0.001  Tetracyclines2100.6%150.3%0.004  Tigecycline4851.5%1102.2%\<0.001  Aztreonam13194.0%2585.2%\<0.001*Hospital Characteristics* Area  Midwest884827.0%113322.7%\<0.001  Northeast439713.4%95019.1%  South13,57941.5%195139.1%  West588618.0%95019.1% Number of Beds   \< 200559717.1%74414.9%\<0.001  200 to 299750823.0%117123.5%  300 to 49910,54032.2%178135.7%  500+906527.7%128825.8%  Teaching12,09637.0%198839.9%0.217  Urban29,41889.9%457491.8%\<0.001  *Hospital outcomes*  Mortality32349.9%60712.2%\<0.001  Mean (SD) LOS, days9.0 (8.5)14.7 (19.4)\<0.001  Median \[IQR\] LOS, days7 \[4, 11\]9 \[5, 16\]\<0.001  Mean (SD) costs, \$20,227 (25,616)33,216 (49,567)\<0.001  Median \[IQR\] costs, \$12,719 \[7401, 23,275\]17,386 \[9255, 35,625\]\<0.001*Hospital outcomes stratified by infection type* UTI  Mortality15488.6%26710.6%\<0.001  Mean (SD) LOS, days8.5 (7.8)13.3 (17.1)\<0.001  Median \[IQR\] LOS, days6 \[4, 10\]9 \[5, 15\]\<0.001  Mean (SD) costs, \$18,103 (21,440)28,069 (40,490)\<0.001  Median \[IQR\] costs, \$11,862 \[7015, 21,222\]16,209 \[8828, 31,535\]\<0.001 Sepsis  Mortality135612.6%26017.7%\<0.001  Mean (SD) LOS, days9.9 (9.9)18.9 (23.3)\<0.001  Median \[IQR\] LOS, days7 \[4, 12\]12 \[6, 22\]\<0.001  Mean (SD) costs, \$24,532 (32,043)47,881 (64,812)\<0.001  Median \[IQR\] costs, \$15,048 \[8312, 28,558\]25,121 \[12,382, 55,529\]\<0.001 Pneumonia  Mortality3308.4%808.0%0.726  Mean (SD) LOS, days8.5 (7.6)12.0 (17.6)\<0.001  Median \[IQR\] LOS, days7 \[4, 10\]7 \[4, 13\]\<0.001  Mean (SD) costs, \$18,220 (21,710)24,623 (38,753)\<0.001  Median \[IQR\] costs, \$11,742 \[7125, 20,561\]13,040 \[7393, 26,339\]\<0.001*IET* inappropriate empiric therapy, *SD* standard deviation, *ECF* extended care facility, *AIDS* acquired immune deficiency syndrome, *IQR* interquartile range, *HCA* healthcare-associated, *CSE* carbapenem sensitive Enterobacteriaceae, *CRE* carbapenem resistant Enterobacteriaceae, *UTI* urinary tract infection, *ICU* intensive care unit, *IQR* interquartile range 25--75%

In a parse generalized regression model exploring the impact of CRE on the risk of IET, resistance was the single strongest predictor of receiving IET (adjusted relative risk ratio 3.95, 95% confidence interval 3.51, 4.46, *p* \< 0.001) (Table [5](#Tab5){ref-type="table"}). The confirmatory analyses produced similar risk ratios (Table [5](#Tab5){ref-type="table"}).Table 5Adjusted risk of inappropriate empiric therapy, hospital mortality, excess LOS and costsMarginal effect, CSEMarginal effect, CREAdjusted relative risk ratio/excess days or costs (95% confidence interval)*P*-value*Risk of IET* Parse Model11.8%47.7%3.95 (3.51, 4.46)\<0.001 Propensity score (based on 100% CRE cases matched to CSE 1:1)13.1%55.8%4.27 (3.64, 5.00)\<0.001 Non-parse model11.9%47.7%4.00 (3.48, 4.59)\<0.001Marginal effect, non-IETMarginal effect, IETAdjusted relative risk ratio/excess days or costs (95% confidence interval)*P*-value*Risk of death* Hierarchical model9.8%11.0%1.12 (1.03, 1.23)0.013 Propensity score (based on 96.4% IET cases matched to non-IET 1:1)10.5%11.9%1.13 (1.01, 1.27)0.030*Length of stay (days)* Hierarchical model8.213.45.2 (4.8, 5.6)\<0.001 Propensity score (based on 96.4% IET cases matched to non-IET 1:1)9.614.65.0 (4.4, 5.6)\<0.001*Hospital costs* Hierarchical model\$20,508\$30,819\$10,312 (\$9497, \$11,126)\<0.001 Propensity score (based on 96.4% IET cases matched to non-IET 1:1)\$22,005\$32,837\$10,831 (\$9254, \$12,409)\<0.001*IET* inappropriate empiric therapy, *CSE* carbapenem sensitive Enterobacteriaceae, *CRE* carbapenem resistant Enterobacteriaceae

In a hierarchical regression model adjusting for all confounders (demographics, comorbidities, severity of illness measures, hospital characteristics) IET was associated with an increased risk of in-hospital mortality (adjusted relative risk ratio 1.12; 95% confidence interval 1.03, 1.23, *p* = 0.013) (Table [5](#Tab5){ref-type="table"}). In other hierarchical models, the excess LOS and costs associated with IET exposure were 5.2 days (95% confidence interval 4.8, 5.6, *p* \< 0.001) and \$10,312 (95% confidence interval \$9497, \$11,126, *p* \< 0.001). Propensity-matched analyses produced similar estimates (Table [5](#Tab5){ref-type="table"}).

An interaction term suggested a greater impact on mortality of IET in the setting of sepsis, which prompted a sensitivity analysis in the group whose organisms were cultured from blood. In this set of analyses, including 12,807 patients (186 CRE, 1.5%), the impact of IET on mortality was indeed greater (relative risk ratio 1.55, 95% confidence interval 1.18 to 2.03) than in the overall cohort.

Discussion {#Sec9}
==========

We demonstrate in this large multicenter observational cohort that among patients admitted from the community with a UTI, sepsis or pneumonia, over 17% have an infection with Enterobacteriaceae, of which approximately 3% are CRE. Although infrequent, the presence of CRE increases the risk of receiving IET substantially. In turn, receiving IET is associated with a rise in hospital mortality, LOS and costs, a rise particularly pronounced in patients with sepsis.

Multiple studies have noted an increase in the prevalence of CRE among patients with serious infections in the hospital. A recent US surveillance study reported the annual population incidence of CRE infections to be nearly 3 cases per 100,000 population \[[@CR28]\]. A US Centers for Disease Control and Prevention study noted a rise in CRE prevalence from 1.2% in 2001 to 4.2% in 2011 \[[@CR29]\]. The same study analyzing a different database, however, noted an increase in CRE from 0 in 2001 to 1.4% in 2010, echoing findings of other investigators \[[@CR19], [@CR30], [@CR31]\]. Our findings are generally in agreement with these numbers. Although CRE incidence and prevalence are far lower than such common pathogens as methicillin-resistant *Staphylococcus aureus* or *Clostridium difficile*, there are few treatment alternatives for CRE, which underscores the need for more precise information about the epidemiology and outcomes related to CRE infections \[[@CR32], [@CR33]\]. Consequently, this study helps to address this need for more granular information regarding this pathogen. In addition we confirm that at this point, CRE is encountered most often as a urinary pathogen, which may mediate the otherwise high mortality rate associated with CRE infections. Despite this, the increasing frequency of this organism as a cause of sepsis indicates that CRE is poised to become a major contributor to infectious disease related mortality in the US.

Though thought of mostly as healthcare-associated pathogens, our data suggest that this may be too narrow a view. Namely, in our cohort, over 40% of patients with CRE did not have an identifiable exposure to the healthcare system. There are several potential sources for misclassifying this burden, one of which may be the 90-day period for prior hospitalization as a risk factor for HCA infection. Though it remains unclear how long the impact of prior hospitalization persists on the risk of resistance, and 90 days is a standard interval used in many other studies, in some investigations this period is longer \[[@CR34]\]. Although a probable overestimate due to misclassification and because of limitations in the patient records, our data are not the first to bring into question this assumption in a US population. In the surveillance study of CRE by Guh et al., 2/3 of the cultures derived from the outpatient setting \[[@CR35]\]. More importantly, 8% lacked any markers of healthcare exposure \[[@CR35]\]. In an additional small study by Tang et al., community-acquired CRE accounted for 30% of all CRE infections \[[@CR36]\]. Though higher in our study, the fact remains that persons with no ongoing relevant exposure to the healthcare system may still contract an infection with this organism. This finding is troubling in that it parallels what has been observed with extended-spectrum beta-lactamase carrying pathogens and their increasing prevalence in community-acquired infections \[[@CR37]--[@CR40]\].

There is mounting evidence to demonstrate that rising antimicrobial resistance impedes clinical efforts at instituting appropriate empiric treatment \[[@CR14]\]. We confirm the important role resistance plays in thwarting the ability to choose appropriately, whereby the risk of receiving IET in the setting of CRE rose 4-fold compared to CSE. In turn, though modest, IET's adverse impact on hospital mortality is consistent with what has been reported in other infections \[[@CR1]--[@CR13]\]. The more pronounced impact of IET on hospital LOS (\~5 excess days) and costs (\~additional \$10,000) is a novel finding for infections with CRE, and provides a sound rationale for investing in technologies that identify patients at risk for CRE more rapidly, particularly given that this is approximately double the attributable burden reported in infections caused by other resistant organisms \[[@CR41]\]. Moreover, having a precise estimate of the attributable costs of these infections helps put into perspective the potential value of various prevention and treatment paradigms. It is methodologically challenging to estimate the attributable impact of carbapenem resistance on cost and LOS in nosocomial CRE infections since those outcomes are confounded by the cause of the initial hospitalization. Therefore, our findings help clarify this issue.

Our study has a number of strengths and limitations. The limitations that are common to both the current and previous studies are discussed in citation \#22. Specific to the current analysis, a potential source of misclassification is a relatively high prevalence of *Proteus mirabilis* as a pathogen, as this microbe may have naturally occurring higher MICs for imipenem (Table [1](#Tab1){ref-type="table"}) \[[@CR42], [@CR43]\]. Since susceptibility data in Premier are reported not by the MIC, but by susceptibility designation (S, I, R, see above in Methods), for the purpose of this analysis we had to presume that clinical adjudication occurred at each individual institution. However, this type of misclassification, if present, is likely to lead to an underestimate of the impact of CRE on outcomes, thus suggesting that in fact, CRE, when determined without this potential misclassification, may have an even greater effect on the risk of IET exposure.

Conclusions {#Sec10}
===========

In summary, CRE is an uncommon but important pathogen in community-onset UTI, pneumonia and sepsis. We confirm that, similar to other resistant organisms, it evades appropriate empiric treatment and exposure to IET worsens both clinical and economic outcomes. Although the true extent of the problem requires further study, our data confirm that a substantial proportion of CRE may be acquired in the community irrespective of exposure to the healthcare system. In sum, our study provides compelling evidence to hasten development of rapid identification methods and new antibiotic treatments in order to optimize empiric therapy among hospitalized patients with serious infections.

CA

:   Community-acquired

CRE

:   Carbapenem-resistant Enterobaceriaceae

CSE

:   Carbapenem-sensitive Enterobacteriaceae
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:   Healthcare-associated

ICU

:   Intensive care unit

IET

:   Inappropriate empiric therapy

LOS

:   Length of stay

UTI

:   Urinary tract infection
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